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Purpose: Studies of genetic variation in the prostate-specific antigen (PSA) gene have 
improved the diagnostic accuracy of PSA for diagnosing prostate diseases in 
Caucasians. However, the reference ranges and pharmacokinetics of PSA differ sig-
nificantly according to race. Therefore, we evaluated the association between genetic 
variations in the PSA promoter area and benign prostatic hyperplasia (BPH) pheno-
types in Korean BPH patients. 
Materials and Methods: One hundred twenty-one men were enrolled. The initial serum 
PSA level, prostate size, and PSA changes at 3 months after treatment with dutasteride 
were determined. We amplified the promoter region of the PSA gene (nucleotide posi-
tions −158 to −356 and −5217 to −5429) and sequenced the products.
Results: Three relatively well characterized single-nucleotide polymorphisms (SNPs; 
rs3760722, rs266867, and rs266868), six uncharacterized SNPs (rs17554958, 
rs266882, rs4802754, rs2739448, rs2569733, and rs17526278), and one novel SNP 
(nucleotide position −5402) were found. There were no statistically significant correla-
tions between any of the SNPs of the PSA promoter area and age-adjusted prostate sizes, 
initial PSA levels, or PSA variations after 3 months of dutasteride treatment. 
Conclusions: SNPs in the PSA promoter area were not associated with BPH phenotypes. 
We could not predict serum PSA changes after dutasteride treatment on the basis of 
PSA promoter genotype in Korean patients with BPH. 
Key Words: Phenotype; Prostate-specific antigen;  Prostatic hyperplasia; Single-nucleotide 
polymorphism
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INTRODUCTION
The incidence of benign prostatic hyperplasia (BPH) in-
creases with advancing age [1]. Even though several hy-
potheses regarding the trigger for BPH have been sug-
gested, BPH is mainly caused by augmented levels of an-
drogen or dihydrotestosterone (DHT) [2,3]. 5α-Reductase 
inhibitors (5ARIs) are currently available for reducing the 
intra-prostatic DHT level, resulting in a reduction of serum 
prostate-specific antigen (PSA) [2-4]. 
　Because the prostate is the major site of PSA expression 
in men, serum PSA levels have become the most widely 
used marker for prostate cancer (PC) screening and for 
monitoring patient responses to therapeutic interventions 
[5,6]. However, PSA has several limitations, including a 
low specificity and low sensitivity for PC detection [7]. 
Furthermore, PSA levels are highly variable over time. In 
addition, serum PSA levels after treatment with a 5ARI ex-
hibit a considerable degree of variability [3,8]. Therefore, 
the inconsistent effect of 5ARIs on serum PSA levels has Korean J Urol 2010;51:824-830
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TABLE 1. Clinical and demographic characteristics of study 
subjects
No. of patients
Age (yr)
Prostate size (cc)
　＜30
　30-50
　＞50
　Not taken
Initial serum PSA (ng/ml)
　＜4 
　4-10 
　＞10 
　Not taken
PSA changes
a
　＜0.5
　0.5-1
　＞1
　Not taken
121
70.33±6.92
59.2±28.76
12
37
56
16
6.56±8.48
58
47
16
  0
0.75±0.47
34
65
19
  3
PSA: prostate-specific antigen, 
a:
 PSA level at 3 months/initial
PSA level
FIG. 1. Schematic structure and single-nucleotide sequence polymorphisms in two prostate-specific antigen promoter areas (−158 to
−356 and from −5217 to −5429) with respect to the start of transcription
a and contig positions of NT011109.15
b. 
a: respect to the start
of transcription, 
b: respect to the contig positions of NT11109.15.
limited our ability to differentiate BPH from PC. To over-
come the limitations of using PSA diagnostically, research 
on PSA kinetics in prostate diseases has progressed consid-
erably in the last decade [9,10]. 
　Recently, Cramer et al reported that genetic variations 
in the PSA promoter are associated with serum PSA levels 
[10]. Thus, an understanding of the PSA promoter geno-
type may help us to understand PSA kinetics after dutas-
teride treatment and to develop models of PSA cutoff values 
to increase the sensitivity or specificity for detecting PC. 
But whether or not the findings regarding the PSA pro-
moter genotype are universal or applicable to the European 
population alone is not known because reference ranges of 
PSA differ significantly according to race [11,12]. Further-
more, because the enrolled population in that study com-
prised workers exposed to asbestos, the serum PSA levels 
or genetic phenotypes were not representative of BPH pa-
tients [10]. Because there is a significant overlap in PSA 
values between patients with BPH and those with PC, and 
because BPH and PC frequently co-exist in aging men, a 
genetic study involving BPH patients, not the general pop-
ulation, must be performed to understand PSA pharmaco-
kinetics and to differentiate BPH from PC.
　Our aim was to evaluate the variations in the PSA pro-
moter gene in Korean patients with BPH, as well as to com-
pare the results with BPH phenotypes and serum PSA 
changes after dutasteride treatment. We also focused on 
differences in the PSA promoter gene among different eth-
nicities that may reflect the different phenotypes in pros-
tate diseases. 
MATERIALS AND METHODS
1. Study population 
The study population comprised 121 Korean men with a 
clinical diagnosis of BPH (Table 1). Informed consent was 
obtained from the study participants. The research proto-
col was approved by the Institutional Review Board of the 
Dankook University Hospital. 
　Patients with a serum PSA level ＞4 ng/ml underwent 
transrectal biopsy to exclude PC. Blood samples were col-
lected in tubes containing sodium ethylenediamine tetra-
acetic acid (EDTA) [13]. We used a QIAmp blood extraction 
kit (Qiagen, Valencia, CA, USA) for DNA extraction. Serum 
PSA levels were determined with a PSA kit (PSA-RIACT; 
CIS Bio International, Gif Sur Yvette, France). Prostate 
size was determined through transrectal ultrasound (HD7 
Ultrasound System; Philips, Shenyang, China). We pre-
scribed one tablet of dutasteride (0.5 mg/day; GSK, 
Beinheim, France) for 3 months and determined serum 
PSA changes by serial testing. PSA changes were calculated 
as a ratio (PSA level at 3 months/initial PSA level). Three 
people were lost to follow-up. 
2. Laboratory assay
DNA samples from the 121 subjects were amplified by poly-
merase chain reaction (PCR). All PCR products yielded 
specific amplifications, but approximately 6% of the sam-
ples failed to yield specific genetic information or yielded 
partially ambiguous DNA sequencing data. The ambiguous 
sequencing data at specific single-nucleotide polymor-
phism (SNP) sites were excluded from the data analysis. 
　We performed PCR to amplify 2 regions in the PSA pro-
moter gene (−158 to −356 and −5217 to −5429 from the 
transcription start site; Fig. 1). The primer sequences of the 
−158 to −356 region were 5'-GGGATCAGGGAGTCTCA 
CAA-3' and 5'-AAACCTTCATTCCCCAGGAC-3', respec-
tively. The primer sequences of the −5217 to −5429 region 
were 5'-TGTTAGCCAGGATGGTCTCA-3' and 5'-CCTCA 
GAGCCTGAGAGGTCA-3', respectively. The PCR was Korean J Urol 2010;51:824-830
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FIG. 2. Representative single-nucleotide sequence polymorphisms (arrows) in this study. One polymorphism at −206 (rs17554958)
was a T insertion or deletion variation, and the other nine polymorphisms showed a typical SNP phenotype, two homotypes, and one 
heterotype.
performed in a 2720 Thermal Cycler (Applied Biosystems, 
Foster City, CA, USA). We used 25 to 70 ng of genomic DNA 
as a template in a total PCR volume of 50 μl. Each tube con-
tained 25 μl of 2x GoTaq Green Master Mix (400 μM dATP, 
400 μM dGTP, 400 μM dCTP, 400 μM dTTP, and 3 mM 
MgCl2; Promega, Madison, WI, USA), 300 nM of each oligo-
nucleotide primer, and 2 μl of extracted DNA template. All 
reaction samples were heated to 94
oC for 5 minutes and were 
then subjected to 30 cycles at 95
oC for 1 minute, 55
oC for 
1 minute, and 72
oC for 1 minute. A final extension was per-
formed at 72
oC for 5 minutes. After purification (Bioneer, 
Daejeon, Korea), we identified the sequences with a BigDye 
Terminator Sequencing Kit (Applied Biosystems) using 
the above four primers.
3. Statistical methods
Hardy-Weinberg equilibrium tests for all genotyped SNPs 
and pairwise linkage disequilibrium tests for all pairs of 
genotyped SNPs were performed by using the Haploview 
program [14]. Lewontin’s D' was used to estimate the 
strength of pairwise linkage disequilibrium. An associa-
tion between the genetic variations and BPH phenotypes 
was estimated by using SPSS ver. 11.0 (SPSS Inc., Chicago, 
IL, USA). p-values＜0.05 were considered statistically 
significant.
RESULTS
We identified 10 SNPs in this region (Fig. 1, 2). Three rela-
tively well-characterized SNPs (rs3760722, rs266867, and 
rs266868), six uncharacterized SNPs (rs17554958, rs266-
882, rs4802754, rs2739448, rs2569733, and rs17526278), 
and one novel SNP (nucleotide position −5402) were 
found. One polymorphism at −206 (rs17554958) was a T 
insertion or deletion variation (Fig. 2), and the other nine 
polymorphisms showed a typical SNP phenotype: two ho-
mogenotypes and one heterogenotype. Because the rs376-
0722 significantly deviated from the Hardy-Weinberg 
equilibrium (HWE; p=0.002), it was removed from further 
statistical analysis. 
　The 121 study subjects had a Mean±SD age of 70.33±6.92 
years and a mean serum PSA concentration of 6.56±8.48 
ng/ml. There were no significant differences in the age in-
tervals among genetic variations in each SNP. No SNPs 
were associated with the initial serum PSA level, prostate 
volume, or PSA changes after 3 months of dutasteride 
treatment (p＞0.05, chi-square test) (Table 2). We used 
haplotype analysis in eight SNPs by using the Haploview 
program. The results showed one typical haplotype at 
−5217, −5307, and −5412. Haplotype 1 (TGC), haplotype 
2 (TAT), haplotype 3 (AGT), and haplotype 4 (TGT) had an Korean J Urol 2010;51:824-830
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TABLE 2. Serum PSA levels, prostate volume, and SNPs in PSA promoter region
SNP/genotype n Prostate volume (cc) n Initial PSA levels (ng/ml) n PSA changes
rs266882
　CC 65 59.51±29.18 76 5.84±5.83 75 0.71±0.47
　CT 34 57.01±23.8 37   7.78±12.44 36 0.68±0.5 
　TT   0   1   1
rs17554958
　Deletion 43   57.8±28.06 49   6.73±10.84 49 0.75±0.57
　Insertion 53 59.51±27.24 62 6.23±6.45 61 0.66±0.39
rs4802754
　CC 44 58.24±27.88 50   6.82±10.75 50 0.75±0.57
　CT 37 57.02±26.90 44 5.59±5.41 42 0.61±0.25
　TT 18 62.68±28.13 20 7.65±8.02 20 0.78±0.57
rs17526278
　CC 74 60.44±27.07 88 6.88±9.38 87 0.69±0.46
　CT 20 63.63±36.13 22 6.81±5.95 22 0.66±0.26
　TT   3 34.07±7.15   3 1.47±1.42   3 1.26±1.54
rs266867
　AA   3 49.71±18.25   3 2.34±1.33   3 0.45±0.11
　AT 24 60.48±33.75 31 6.59±7.71 30 0.79±0.56
　TT 72 60.04±28.01 80 6.68±9.12 78 0.69±0.46
rs266868
　AA 14 56.12±27.04 14 10.89±19.11 14 0.76±0.72
　AG 36 64.53±30.18 46 5.51±3.93 46 0.71±0.48
　GG 49 57.44±28.95 54 6.29±7.08 51 0.70±0.42
New SNP 
　CC 102 59.46±29.04 118 6.64±8.57 115 0.71±0.48
　CT   2 54.60±22.48   2 4.18±3.01   2   0.43±10.10
　TT   1   1   1
rs2739448
　CC 22 61.65±27.51 24 6.08±6.02 22 0.75±0.52
　CT 40 58.78±27.41 47 6.14±6.37 46 0.63±0.30
　TT 37 59.90±32.31 43   7.24±11.63 43 0.78±0.61
rs2569733
　GG 20 60.78±28.41 22 5.74±6.14 20 0.76±0.55
　GT 41 59.40±27.36 48 6.26±6.36 47 0.63±0.30
　TT 38 59.81±31.88 44   7.25±11.49 44 0.77±0.60
PSA: prostate-specific antigen, SNP: single nucleotide polymorphism
TABLE 3. Association of PSA promoter haplotype and initial serum PSA levels
Haplotype
Allele
Frequency
Initial PSA level
ng/ml (Mean±SD)
p-value
Age (yr)
Mean±SD
p-value −5217A/T 
SNP
−5307A/G 
SNP
−5412C/T 
SNP
1
2
T
AA or AT
AA or AG
GG
C
TT or CT
0.388
0.553
8.96±11.51
4.85±5.30
0.012 70.89±6.96
69.86±6.75
0.432
PSA: prostate-specific antigen, SNP: single nucleotide polymorphism
estimated frequency of 41.7%, 31.5%, 15.2%, and 10.6%, 
respectively.
　We tested whether specific combinations of these se-
quence variants were associated with BPH phenotypes. As 
shown in Table 3, our study population had two major hap-
lotypes. Men who had one copy of the −5217 TT/−5307AA 
or AG/−5412CC haplotype had significantly higher PSA 
levels than did men who had copies of the −5217AA or AT/
−5307 GG/−5412 TT or CT haplotypes (p=0.012, adjusted 
for age). However, other phenotypes, such as prostate size 
and PSA changes after dutasteride, were not associated 
with the above haplotype. Pairwise linkage disequilibrium 
tests demonstrated that some of the SNPs examined in the 
PSA promoter gene were in strong linkage disequilibrium, Korean J Urol 2010;51:824-830
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TABLE 4. Pairwise test of linkage disequilibrium of SNPs in the PSA promoter area
SNP
SNP  −158  −252  −285  −5217  −5307  −5402  −5412  −5429
−158   0.88 0.63 0.72 0.45 0.19 0.52 0.60
−252  1.0 0.74  1.0 1.0 0.95  0.93 
−285  0.15 0.74 0.12 0.47  0.63
−5217 1.0  1.0 1.0 1.0
−5307  1.0 1.0 1.0
−5402  1.0 1.0
−5412  0.97
−5429
SNP: single nucleotide polymorphism, PSA: prostate-specific antigen, The diagonal figures represent the absolute value of Lewontin’s D'
but others were not (Table 4). 
DISCUSSION
Testosterone is converted to the potent DHT by a steroid 
5α-reductase enzyme that binds to and activates the an-
drogen receptor (AR) [2]. The activated AR mediates and 
up-regulates the expression of PSA through androgen re-
sponse elements (AREs) in the promoter gene. Interven-
tions that inhibit 5α-reductase enzyme inactivate the AR 
and down-regulate serum PSA levels [2,15]. Thus, the me-
dian change in PSA in dutasteride-treated patients is 
−59.5% at 2 years, which increases to −66.1% at 4 years 
[3]. Our study evaluated the early changes in serum PSA 
after dutasteride treatment; the serum PSA level was re-
duced 25% from initial PSA levels.  
　The serum PSA levels after 5ARI treatment are gen-
erally reduced; however, there are interindividual varia-
tions in the reduced PSA levels. It is difficult to differentiate 
patients with BPH from those with PC because of the varia-
tion in PSA levels; thus, an understanding of PSA pharma-
cokinetics and the prediction of individual PSA changes af-
ter treatment with 5ARIs is of enormous practical sig-
nificance [3,10,16].
　Xue et al reported that serum PSA is associated with PSA 
genotype at −158, with higher PSA levels among men with 
the PSA AA genotype than among men with the AG or GG 
genotypes [17]. This polymorphism has also been asso-
ciated with an increased risk for the development of PC 
[18,19]. However, another group reported that this poly-
morphism was not associated with the serum PSA level in 
two separate groups of men without PC [20,21].
　In a recent study, SNPs in the PSA promoter gene near 
−6 kb in the 5' region (the −4643G/A SNP [G allele], the 
−5412C/T SNP [C allele], and the −5429T/G SNP [G al-
lele]) were associated with increases in serum PSA levels. 
Those authors concluded that genetic variations in the PSA 
promoter gene are associated with serum PSA levels in men 
without prostatic disease [10]. Thus, the PSA promoter 
genotype may help to develop models of PSA cutoff values 
[10,18,19]. 
　Each individual has a change in DNA sequence of ap-
proximately 1 DNA base in every 200 to 300 bases com-
pared with other individuals [22]. The ARE areas in our 
study involved 10 SNPs in approximately 800 bp. A high 
incidence of SNPs in an ARE area may be responsible for 
different phenotypes or inherited individual differences in 
BPH or PC phenotypes.
　Three polymorphism sites (rs3760722, rs266867, and 
rs266868) are well characterized in the HapMap infor-
mation. The genotypes of the rs266868 polymorphism in 
Japanese and Chinese populations from HapMap data 
were as follows: GG type, 36% and 47%; AG type, 45% and 
46%; and AA type, 18% and 6%, respectively. Our data for 
the rs266868 polymorphism, which were very similar to the 
results from HapMap data, were as follows: GG type, 47.3%; 
AG type, 40.3%; and AA type, 12.2%. The genotype of the 
rs266867 polymorphism in Japanese and Chinese pop-
ulations was as follows: AA type, 1.2% and 3.6%; AT type, 
29.4% and 38.1%; and TT type, 69.4% and 58.3%, respec-
tively. Our data for the rs266867 polymorphism were as fol-
lows: AA type, 2.6%; AT type, 27.1%; and TT type, 70.1%.
　Six uncharacterized SNPs (rs17554958, rs266882, rs4-
802754, rs2739448, rs2569733, and rs17526278) were 
found. The polymorphism at −206 (rs17554958) was a T 
insertion or deletion variation, whereas the other five poly-
morphisms showed two homogenotypes and one hetero-
genotype. One novel SNP (nucleotide position −5402) was 
also found. Because the incidence of the CT and TT geno-
types is rare (1.6% and 0.8% in the novel SNP), large num-
bers of samples are needed for a complete characterization. 
　The 121 study subjects from whom the samples were ob-
tained had a mean±standard deviation age of 70.33±6.92 
years and a mean serum PSA concentration of 6.56±8.48 
ng/ml. Because the serum PSA from the enrolled pop-
ulation was higher than that reported in other studies, 
some patients in our study may had coexisting PC. To re-
duce contamination with PC, we routinely obtain prostate 
biopsies in patients with a serum PSA ＞4 ng/ml. Sixteen 
patients with a serum PSA ≥10 ng/ml underwent prostate 
biopsies and follow-up at least 2 years after dutasteride 
treatment. They all showed continuously decreased serum Korean J Urol 2010;51:824-830
Polymorphisms in PSA Gene and BPH Phenotypes 829
PSA levels for 2 years, thus suggesting BPH. It is well 
known that the median PSA level consistently decreases 
from baseline in both patients with and those without PC 
within the early period after dutasteride treatment. 
However, from month 12 on, the median PSA increases in 
patients eventually diagnosed with PC, whereas it con-
tinues to decrease in those without a subsequent diagnosis 
of PC [3,16].
　There were no statistically significant differences in age 
intervals among genetic variations in each SNP. Interes-
tingly, no SNPs were significantly associated with the serum 
PSA level, prostate volume, or PSA changes after 3 months 
of dutasteride treatment (Table 2). Our results were differ-
ent from the report of Cramer et al [10]. There are several 
reasons for these differences. For the most part, the charac-
teristics of the enrolled patients differed. Cramer et al in-
cluded asbestos workers who were recruited for a study of 
the interaction of asbestos exposure with genetic and envi-
ronmental factors [10]. Moreover, their patients were 
younger than our patients, and the median serum PSA con-
centration was lower than the median serum PSA level in 
our patients. Our study population comprised BPH pa-
tients who complained of voiding symptoms. Furthermore, 
all patients who had an ultrasound were shown to have a 
large prostate volume (＞30 cc). It is well known that there 
is a clinically significant relationship between serum PSA 
and prostate volume in men with BPH [6,8]. Our pop-
ulation usually had a large prostate volume, which was the 
indication for dutasteride treatment.
　We must also consider the ethnicity difference between 
Caucasians and Asians. Oesterling et al reported that the 
age-specific reference ranges were lower for serum PSA 
levels and higher for PSA density in Japanese men relative 
to Caucasian men [12]. Because PSA levels depend mark-
edly on age and might be significantly influenced by race, 
a given PSA value may have different clinical meaning for 
patients of different races [11,12].
　We used haplotype analysis in nine SNPs by use of the 
Haploview program. Pairwise linkage disequilibrium 
tests demonstrated that most of the SNPs examined in the 
upper area of the PSA gene promoter (−5307 to −5429) 
were in strong linkage disequilibrium (Table 4). However, 
there was weak linkage disequilibrium between the −158 
SNP and the upper area of the PSA gene. Our results dif-
fered from those of Cramer et al, who reported linkage dis-
equilibrium between the −158 SNP and further upstream 
SNPs [10]. This suggests that there are ethnicity differ-
ences in the PSA gene between Caucasians and Asians. 
Further study will be needed to determine whether the dif-
ferences are attributed to ethnicity or different disease 
phenotypes.
　Our results showed 1 haplotype at −5217, −5307, and 
−5412. Haplotype 1 (TGC), haplotype 2 (TAT), haplotype 
3 (AGT), and haplotype 4 (TGT) had an estimated frequen-
cy of 41.7%, 31.5%, 15.2%, and 10.6%, respectively. Interes-
tingly, men who had copies of the −5217TT/−5307AA or 
AG/−5412CC haplotype had a significantly higher PSA 
level than did men who had copies of the −5217AA or AT/ 
−5307 GG/−5412 TT or CT phenotype (p=0.012, adjusted 
for age). We could not conclude whether these results were 
clinically meaningful or represent an accidental error. 
CONCLUSIONS
The present findings suggest that genetic variations in the 
PSA promoter gene are not associated with initial PSA lev-
els, prostate volume, or PSA changes after dutasteride 
treatment in Korean patients with BPH. Again, we could 
not predict the serum PSA changes after dutasteride treat-
ment according to PSA promoter genotype alone in Korean 
patients with BPH. However, the finding that 1 haplotype 
in −5217, −5307, and −5412 was associated with the ini-
tial serum PSA level suggests possible genetic involve-
ment. Additional research or a larger enrolled population 
will be needed to determine the mechanisms of different 
patterns of the same PSA promoter gene among different 
racial groups.
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